TNFSF13B and autoimmune pancreatitis type 1: Other therapies for type 1 AIP, including rilzabrutinib (Bruton tyrosine kinase inhibitor), belimumab (B-cell activating factor inhibitor), and inebilizumab (anti-CD19 monoclonal antibody), are under investigation (44).